Study S001485

A Randomized Clinical Trial Comparing Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06057077
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: SINGLE
Status: UNKNOWN
Enrollment: 120
Start: 2024-01-01
Primary completion: 2024-12-31
Lead sponsor: Ministry of Health, Saudi Arabia
Conditions: Type 1 Diabetes
Interventions: DRUG:Semaglutide weekly injection
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

change in HA1c and mounts of insulin of basal and bolus which will be taken daily is the same or decreased after one year of follow up [Time Frame: one year]

Linked records (3)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0008558	Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression. Ahmed A, Advanced pharmaceutical bulletin	2024	Nonrandomized study	PMID 39206389 DOI	cites ClinicalTrials.gov:NCT06057077; registry reference DERIVED:39206389
R0009357	Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Early Type 1 Diabetes Treatment for Albumin-Insulin Producing Cells Expression Ahmed A, Qeios	2023	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT06057077
R0048900	Exploring the Synergistic Approach of Dual GLP-1 Agonist with Degludec Basal Insulin for Type 1 Diabetes Treatment for Albumin-InsulinProducing Cells Expression Amr Kamel Khalil Ahmed, Qeios	2023	Nonrandomized study	DOI	cites ClinicalTrials.gov:NCT06057077